Form 483

CorePharma, LLC Form 483, 2012-06-11

FDA issued a Form 483 to CorePharma, LLC on 2012-06-11 with 9 public-safe observations.

483· Form 483 issued9 observations

CorePharma, LLC · Middlesex, United States · Issued June 11, 2012

Overview

  • 9 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

11 Jun 2012
21 CFR 211.22(a)

Contract drug products--lack of responsibility

Cited by Justine Tomasso, Erin D Mccaffery

11 Jun 2012
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Justine Tomasso, Erin D Mccaffery

11 Jun 2012
21 CFR 211.67(a)

Cleaning / Sanitizing / Maintenance

Cited by Justine Tomasso, Erin D Mccaffery

11 Jun 2012
21 CFR 211.68(b)

Backup data not assured as exact and complete

Cited by Justine Tomasso, Erin D Mccaffery

11 Jun 2012
21 CFR 211.68(b)

Computer control of master formula records

Cited by Justine Tomasso, Erin D Mccaffery

Inspected site

CLCorePharma, LLCMiddlesex, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.68(b)Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.204Cited across public-safe Form 483 observations1x
21 CFR 211.22(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.67(a)Cited across public-safe Form 483 observations1x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 9 observations

The source PDF and every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere